Standard practice is a mid cycle review during phase 3, and knowing the very successful and comprehensive Phase 2b trial of 300 people results, I am very confident that by this point share price will be >$1.40. The mid cycle review should be provided by November this year.
If results show similar during this Phase 3 study to what was in the Phase 2b, this unique medicine will certainly be a blockbuster ($1b sales pa) which will put OPT's value at a baseline of $8b market cap. 16x current market cap. OPT is worth the wait while the study is completed on a drug that they know works and is safe.
OPT is definitely known about by investors and during this gamechanging year for OPT things are going to be exciting for holders.
Standard practice is a mid cycle review during phase 3, and...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
68.0¢ |
Change
0.045(7.09%) |
Mkt cap ! $450.7M | |||
| Open | High | Low | Value | Volume |
| 67.0¢ | 72.0¢ | 65.0¢ | $681.3K | 999.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 9279 | 67.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 68.0¢ | 54 | 1 |
View Market Depth
| Last trade - 14.07pm 10/05/2024 (20 minute delay) ? |
|
|||||
|
Last
68.0¢ |
Change
0.045 ( 7.48 %) |
||||
| Open | High | Low | Volume | ||
| 64.5¢ | 71.5¢ | 64.5¢ | 76368 | ||
| Last updated 14.27pm 10/05/2024 ? | |||||
| OPT (ASX) Chart |